Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence
Pilot Trial on the Efficacy of Contingency Management for Six Months of Cannabis Abstinence Among Adolescents
1 other identifier
interventional
6
1 country
1
Brief Summary
This study is a critically important first-of-its-kind investigation of the potential research utility of using contingency management to examine long-term changes in cannabis use with six months of abstinence. These pilot data will inform a later trial which will focus on testing the longitudinal relationships between adolescent cognition and cannabis use, questions of high and growing public health significance given adolescents' increased access to cannabis with legalization.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 17, 2018
CompletedFirst Posted
Study publicly available on registry
December 24, 2018
CompletedStudy Start
First participant enrolled
July 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 6, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 6, 2019
CompletedResults Posted
Study results publicly available
August 2, 2024
CompletedAugust 2, 2024
February 1, 2024
5 months
December 17, 2018
February 21, 2024
February 21, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Continuous Abstinence Via Progressive Declines in Urine THCCOOH
Cannabis abstinence will be indexed by progressively decreasing quantitative levels (ng/mL) of 11-nor-delta-9-THC-9-carboxylic acid (THCCOOH), the primary cannabis metabolite, in urine. Residual cannabinoid excretion will be differentiated from new cannabis exposure using a statistical model developed by Schwilke and colleagues (2011). This model was empirically derived from urine CN-THCCOOH concentration ratios of consecutively collected specimen pairs (current specimen/prior specimen). This model takes into account the time between collection of specimens, which enhances the accuracy of prediction of new cannabis use. This formula yields an expected CN-THCCOOH ratio associated with specimen pairs during abstinence, and observed ratios that exceed this expected value are interpreted as new cannabis use.
Six months
Study Arms (1)
Abstinent
EXPERIMENTALInterventions
Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
Eligibility Criteria
You may qualify if:
- Male and female adolescents actively enrolled in a middle or high school in the Boston area who are between the ages of 13 and 19 (inclusive);
- Average use of cannabis at least 3 times per week during the 3 months prior to study enrollment;
- Cannabis use reported within 7 days of study enrollment;
- No immediate plan to discontinue cannabis use;
- Have a parent or legal guardian who is competent and willing to provide written informed consent for the active study phase (if under the age of 18);
- Competent and willing to provide written informed assent for the active study phase (if under the age of 18);
- Competent and willing to provide written informed consent (if age 18 or older);
- Able to communicate in English language;
- Have a parent/guardian who can communicate in English language;
- Able to commit to 27 study visits in approximately 6 months;
- Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator.
You may not qualify if:
- \- Any severe developmental delays (including, but not limited to, Autism Spectrum Disorder, Intellectual Disability, and Down Syndrome).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Randi Schuster, PhD
- Organization
- Massachusetts General Hospital
Study Officials
- PRINCIPAL INVESTIGATOR
Randi M Schuster, PhD
Massachusetts General Hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
December 17, 2018
First Posted
December 24, 2018
Study Start
July 1, 2019
Primary Completion
December 6, 2019
Study Completion
December 6, 2019
Last Updated
August 2, 2024
Results First Posted
August 2, 2024
Record last verified: 2024-02